TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06512467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: 200 mg BID,oral administration will start before the first HAIC treatment .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg Q3W,Intravenous infusion will perform before HAIC treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAIC
Description: HAIC,Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours).
Study: NCT05809011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: After enrollment and randomization, the intervention (experimental arm) will be the administration of corticosteroid therapy, added to standard therapy for acute heart failure. Corticosteroid therapy will be administered as a single-bolus intravenous injection of dexamethasone 20 mg (day 1, as soon as possible after randomization), followed by oral prednisone 1 mg/kg daily (maximum 60 mg daily) from day 2 to day 7 after randomization, administered at about 8.00 AM.
Study: NCT04961801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib, tacrolimus, methotrexate
Description: For Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation in Lymphomas and Leukemia
Study: NCT06039254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1780
Description: Single dose in each arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1780
Description: Single dose in each arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-1780
Description: Single dose in each arm
Study: NCT06536985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treatment group
Description: Researchers will collaborate with participants to develop personalized intervention plans, which include physical exercise, oral function training, basic dietary guidance, and detailed oral health knowledge directly related to oral health behaviors. To facilitate better communication and management, a WeChat group will be created to encourage participants to share their daily exercise achievements. In the first week, face-to-face oral function training sessions will be organized for the intervention group at the nursing home activity center. Concurrently, once a week, the intervention group will gather at the nursing home activity center to practice together using illustrated videos. On Wednesdays, educational articles and videos about oral health are sent via text message. On Fridays, a group communication activity is organized to enhance their social connections. Additionally, we will guide elderly participants to master essential internet skills, enabling them to use smartphones to

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contral group
Description: Participants in the control group will receive general lifestyle advice via text message once or twice a week.They will not participate in the intervention\&#39;s fitness routines, online classes, group chats, or films with health educators. Individual workout regimens, goals, or comments are not given by researchers. Participants in the control group\&#39;s complaints or questions will always be answered with basic health information and suggestions. Researchers won\&#39;t ask for individual advice or comments from other professionals.
Study: NCT04855721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR101
Description: Oral ROR-gamma inverse agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR101
Description: Oral ROR-gamma inverse agonist
Study: NCT05900349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinsing
Description: the carbohydrate solution was prepared by dissolving 6.4 g of colorless and odorless maltodextrin in 93.6 mL of water; the mixtures were then adjusted to a 6.4% maltodextrin solution for the participants to rinse their mouths for 20 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine gum
Description: Chewing caffeinated gum for 20 minutes
Study: NCT06549322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The exercise in morning
Description: Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: AM 11:00-11:30

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The exercise in evening
Description: Resistance exercises are in the following order: squat, bench press, deadlift. Each exercise consists of 3 sets with 7 repetitions, using a load of 70% 1RM with 60 sec of rest between sets.~Exercise timing: PM 05:00-05:30
Study: NCT05196503

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Experimental product: product derived from autologous blood, obtained after centrifugation.~Treatment modalities: intraoperative periradicular administration of autologous PRF.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: Experimental product: product derived from autologous blood, obtained after centrifugation.~Treatment modalities: intraoperative periradicular administration of autologous PRF.
Study: NCT04494737

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Program 1
Description: A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Program 2
Description: A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
Study: NCT05095441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C5252
Description: A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C5252
Description: A single dose of C5252 will be administered up to 2mL as intratumoral injection on Day 1.
Study: NCT05798728

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient transcervical foley balloon
Description: These participants will receive a 16-French Foley catheter which will be placed by a physician present in the clinic. The balloon will be inflated with 40 mL of sterile water, and the catheter will then be gently withdrawn so that the balloon applies pressure against the internal os. The catheter will then be taped to the inner thigh.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Vaginal Misoprostol
Description: These participants will receive 25 micrograms of Misoprostol (100- microgram tablet cut into fourths by the hospital pharmacist) inserted vaginally into the posterior fornix every 4 hours and repeated up to a maximum of six doses per our standard hospital protocol.
Study: NCT04576780

Intervention type: OTHER
Intervention: Integrated Large Complex Polyp Referral Pathway
Description: The referring doctor will use a standardized template to send the referral along with its associated video or high-resolution photographs.~Referrals will be reviewed in a consensus fashion by at least 2 expert physicians at St. Michael's Hospital (SMH) on a bi-weekly basis. Polyps will be scored using a standardized evaluation form that documents relevant polyp features to assist the determination of whether a lesion is amenable to curative endoscopic resection.~Cases will be triaged as being: (1) a standard polyp suitable for local removal in the community; (2) a complex polyp requiring expert removal at SMH with priority assigned based on the suspected risk of invasive disease; (3) a polyp that is not amenable to endoscopic resection or that is suspicious for cancer will that be recommended for surgical resection.
Study: NCT06176456

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Active regiment

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Active regiment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tactile artefacts without magnetic pulses
Study: NCT05729815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Sessions focused on relaxations activities (Jacques Choque Method).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loose parts play
Description: Loose parts play-based sessions, with open-ended materials.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined
Description: Sessions focused on loose parts play and relaxation activities.
Study: NCT05959616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Lyophilized S. sonnei 53G strain (Lot 1794)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Lyophilized S. sonnei 53G strain (Lot 1794)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Lyophilized S. sonnei 53G strain (Lot 1794)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Lyophilized S. sonnei 53G strain (Lot 1794)
Study: NCT06186505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirGlove
Description: AirGlove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intraveneous drugs by gently heating the patients arm up as it forces warm air through a double walled polythene glove. In this study, the device will be used on the leg of the participants as means of encouraging circulation to the area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirGlove
Description: AirGlove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intraveneous drugs by gently heating the patients arm up as it forces warm air through a double walled polythene glove. In this study, the device will be used on the leg of the participants as means of encouraging circulation to the area.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirGlove
Description: AirGlove is a unique warming system developed to enable access to the veins in a patients arm for the delivery of intraveneous drugs by gently heating the patients arm up as it forces warm air through a double walled polythene glove. In this study, the device will be used on the leg of the participants as means of encouraging circulation to the area.
Study: NCT05959616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Lyophilized S. sonnei 53G strain (Lot 1794)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei 53G
Description: Lyophilized S. sonnei 53G strain (Lot 1794)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Description: Ciprofloxacin (500 mg orally twice daily for three days),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Description: Ciprofloxacin (500 mg orally twice daily for three days),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Description: Ciprofloxacin (500 mg orally twice daily for three days),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Description: Ciprofloxacin (500 mg orally twice daily for three days),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Description: Ciprofloxacin (500 mg orally twice daily for three days),

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Description: Ciprofloxacin (500 mg orally twice daily for three days),
Study: NCT05397977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical traction group
Description: In the mechanical traction group, 26 people with cervicogenic headache will be traction with the Chattanooga Tru Trac traction device, 6 days a week for 2 weeks.~Persons to be mechanically traction will be placed on their backs on the treatment bed with their necks on the neck collar of the device. After the patients are fixed to the head, the pulling force of the device will start with 10% of the patient's body weight, the device will be set as 60 seconds of pulling force and 20 seconds of relaxation. In subsequent sessions, the pulling force will be gradually adjusted based on the patient's previous traction therapy, tolerance, and symptom response. Each session will take 15 minutes.~Participants will be given 20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound, and the exercise will be given as a home program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manuel traction group
Description: Manual traction, one of Cyriax's neck mobilization techniques, will be applied to the MTG. Vertebrobasilar artery test will be applied to the patients before starting the treatment, and manual traction will be applied to the patients in case the vertebrobasilar artery test is negative. Manual traction technique will be applied to the cervical region for 15 minutes. While applying manual traction, the patient will be placed on his back with his head hanging off the bed. Grasp the occiput with one hand and under the chin with the other. Manual traction will be applied by keeping the neck neutral and the occiput slightly extended. After applying traction for a few seconds, it will be slowly released and returned to the starting position, and the application will be made for 15 minutes.~20 minutes of TENS, 20 minutes of hotpack and 4 minutes of ultrasound will be applied to the participants, and the exercise will be given as a home program.
Study: NCT05241314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning to BREATHE
Description: A 6 session group-based intervention targeting adolescent mindfulness. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
Study: NCT05235464

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard meal
Description: Standard meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High animal protein meal
Description: Meal with high animal protein content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High plant protein meal
Description: Meal with high plant protein content

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High plant protein meal with additional leucine
Description: Meal with high plant protein content and additional leucine
Study: NCT06088381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Observation
Description: Patients on the experimental arm will be under observation only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation per Standard of Care
Description: The low-risk group of patients will be observed per standard of care.
Study: NCT04855721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUR101
Description: Oral ROR-gamma inverse agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06088381

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Treatment per Standard of Care
Description: The high-risk group of patients will receive adjuvant treatment per standard of care (Radiation with or without chemotherapy)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Circulating Tumor DNA test (ctDNA test)
Description: Blood test for diagnostic and surveillance purposes measuring expression of Cell free HPV tumor DNA (ctDNA) in the blood. Patients will undergo ctDNA within 90 days pre-transoral robotic surgery(TORS), 2-14 days post TORS, then every 3 months (except for at 21 months) for 2 year post completion of initial therapy or salvage therapy.
Study: NCT06219928

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: After intubation, saline infusion will be started. The control group will also be infused with the same volume of saline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Group
Description: After intubation, the patient will be started on ketamine infusion at a low dose of 0.25mg/kg/hour.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: After intubation, the patient will be infused at a low dose of 1 mg/kg for the first 10 minutes, then 0.5 mg/kg/hour.
Study: NCT05838755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279
Description: GSK3858279 will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3858279
Description: GSK3858279 will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered
Study: NCT06672731

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: REMS: Radiofrequency Echographic Multi Spectrometry
Description: it is a non invasive ultrasonographic evaluation of bone and muscle quality
Study: NCT06242509

Intervention type: DIAGNOSTIC_TEST
Intervention: Biological samples
Description: Plasma sampling ans stool sampling~* at inclusion~* at 1 month~* at 3 months~* at progression within the 3 months
Study: NCT06482918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer-assisted top-down or bottom-up cognitive remediation using tablets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer-assisted top-down or bottom-up cognitive remediation using tablets
Study: NCT06672731

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: REMS: Radiofrequency Echographic Multi Spectrometry
Description: it is a non invasive ultrasonographic evaluation of bone and muscle quality
Study: NCT06671821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: HRS-7535
Study: NCT06675799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Weekly educational material about sleep health and weekly brief phone coaching calls for a total of 6 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Psychoeducation
Description: Weekly educational materials about healthy habits and weekly brief phone calls to clarify terms or concepts.
Study: NCT06363383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-001
Description: Oral, delayed release formulation of a biologic drug

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MB-001
Description: Oral, delayed release formulation of a biologic drug
Study: NCT05099666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Dosage per protocol, escalation per protocol, IV over 60 minutes (± 5 minute infusion window), schedule per protocol
Study: NCT05241314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning to BREATHE
Description: A 6 session group-based intervention targeting adolescent mindfulness. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After Deployment Adaptive Parenting Tools (ADAPT)
Description: A 14 session group-based mindful parenting intervention originally developed to increase emotion regulation among military caregivers with young children and improve youth adjustment. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
Study: NCT05099666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: Dosage per protocol, escalation per protocol, IV over 60 minutes (± 5 minute infusion window), schedule per protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Dosage per protocol, IV per institutional standards of practice and the FDA package insert, schedule per protocol
Study: NCT05241314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: After Deployment Adaptive Parenting Tools (ADAPT)
Description: A 14 session group-based mindful parenting intervention originally developed to increase emotion regulation among military caregivers with young children and improve youth adjustment. The adapted and merged intervention will be delivered to individual families (home-based) in twice-weekly sessions over a 7-week period by two community health worker interventionists.
Study: NCT04768114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetically-Informed RiskProfile
Description: * Participants will meet with a behavioral interventionist to receive their personalized genetically-informed RiskProfile intervention which incorporates smoking-related genetic risk propensity and phenotypic risk (cigarettes smoked per day) into a risk communication tool designed to activate behavior change, specifically, to increase the use of smoking cessation medications and promote smoking-related behavior change.~* This is a fully remote trial, with intervention delivered via video conferencing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Cessation Advice
Description: * Participants will meet with a behavioral interventionist to receive standardized brief advice to quit smoking and encouragement to use freely-available smoking cessation resources. Participants will receive their personalized RiskProfile after all data collection has been completed.~* This is a fully remote trial, with brief cessation advice delivered via video conferencing.
Study: NCT06115031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: General anesthesia will be induced and maintained using continuous infusion of intravenous remimazolam.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia will be induced and maintained using target-controlled infusion of intravenous propofol.